[1] |
World Health Organization . Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
|
[2] |
Merkler AE, Reynolds AS, Gialdini G , et al. Neurological complications after tuberculous meningitis in a multi-state cohort in the United States. J Neurol Sci, 2017, ( 375):460-463.
|
[3] |
Marais S, Thwaites G, Schoeman JF , et al. Tuberculous meningi-tis: a uniform case definition for use in clinical research. Lancet Infect Dis, 2010,10(11):803-812.
doi: 10.1016/S1473-3099(10)70138-9
URL
|
[4] |
Thwaites GE, Van Toorn R, Schoeman J . Tuberculous meningi-tis: more questions, still too few answers. Lancet Neurol, 2013,12(10):999-1010.
doi: 10.1016/S1474-4422(13)70168-6
URL
|
[5] |
Chiang SS, Khan FA, Milstein MB , et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis, 2014,14(10):947-957.
doi: 10.1016/S1473-3099(14)70852-7
URL
|
[6] |
Andronikou S, Smith B, Hatherhill M , et al. Definitive neuroradiological diagnostic features of tuberculous meningitis in children. Pediatr Radiol, 2004,34(11):876-885.
doi: 10.1007/s00247-004-1237-1
URL
|
[7] |
Wu XR, Yin QQ, Jiao AX , et al. Pediatric tuberculosis at Beijing Children’s Hospital: 2002—2010. Pediatrics, 2012,130(6):e1433-e1440.
doi: 10.1542/peds.2011-3742
URL
|
[8] |
杨燕, 张侠 . 影响80例结核性脑膜炎患者近期疗效相关因素分析. 中国防痨杂志, 2012,34(5):327-330.
|
[9] |
Modi M, Sharma K, Prabhakar S , et al. Clinical and radiologi-cal predictors of outcome in tubercular meningitis: A prospective study of 209 patients. Clin Neurol Neurosurg, 2017, ( 161):29-34.
|
[10] |
Nataprawira HM, Ruslianti V, Solek P , et al. Outcome of tuberculous meningitis in children: the first comprehensive retrospective cohort study in Indonesia. Int J Tuberc Lung Dis, 2016,20(7):909-914.
doi: 10.5588/ijtld.15.0555
URL
|
[11] |
Dastur DK, Manghani DK, Udani PM . Pathology and pathogenetic mechanisms in neurotuberculosis. Radiol Clin North Am, 1995,33(4):733-752.
|
[12] |
Lu CH, Chang WN, Chang HW . The prognostic factors of adult tuberculous meningitis. Infection, 2001,29(6):299-304.
doi: 10.1007/s15010-001-1100-3
URL
|
[13] |
Lammie GA, Hewlett RH, Schoeman JF , et al. Tuberculous cerebrovascular disease: A review. J Infect, 2009,59(3):156-166.
doi: 10.1016/j.jinf.2009.07.012
URL
|
[14] |
Graham SM, Donald PR . Death and disability: the outcomes of tuberculous meningitis. Lancet Infect Dis, 2014,14(10):902-904.
doi: 10.1016/S1473-3099(14)70872-2
URL
|
[15] |
Schoeman JF, Janse van Rensburg A, Laubscher JA , et al. The role of aspirin in childhood tuberculous meningitis. J Child Neurol, 2011,26(8):956-962.
doi: 10.1177/0883073811398132
URL
|
[16] |
Misra UK, Kalita J, Nair PP . Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci, 2010,293(1-2):12-17.
doi: 10.1016/j.jns.2010.03.025
URL
|
[17] |
Mai NT, Dobbs N, Phu NH , et al. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. Elife, 2018, 7. pii: e33478.
doi: 10.7554/eLife.33478
URL
|
[18] |
邹丹, 刘泉波 . 儿童结核性脑膜炎死亡危险因素分析. 中华临床医师杂志(电子版), 2016,10(12):1727-1731.
|
[19] |
Mangtani P, Abubakar I, Ariti C , et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis, 2014,58(4):470-480.
doi: 10.1093/cid/cit790
URL
|
[20] |
谢本维, 杜翔, 小平措 , 等. 64例结核性脑膜炎患者的预后及相关因素分析. 中华实验和临床感染病杂志(电子版), 2014,8(1):59-62.
|
[21] |
吴晓光, 李雪莲, 陈红梅 , 等. 结核性脑膜炎患者死亡危险因素分析. 中国临床医生杂志, 2015,44(8):29-32.
|
[22] |
Heemskerk AD, Nguyen MTH, Dang HTM , et al. Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen. Clin Infect Dis, 2017,65(1):20-28.
doi: 10.1093/cid/cix230
URL
|
[23] |
Beer R, Engelhardt KW, Pfausler B , et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother, 2007,51(1):379-382.
doi: 10.1128/AAC.00515-06
URL
|
[24] |
Tsona A, Metallidis S, Foroglou N , et al. Linezolid penetration into cerebrospinal fluid and brain tissue. J Chemother, 2010,22(1):17-19.
doi: 10.1179/joc.2010.22.1.17
URL
|
[25] |
Luque S, Grau S, Alvarez-Lerma F , et al. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents, 2014,44(5):409-415.
doi: 10.1016/j.ijantimicag.2014.07.001
URL
|
[26] |
Alffenaar JW, van Altena R, Harmelink IM , et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet, 2010,49(8):559-565.
doi: 10.2165/11532080-000000000-00000
URL
|
[27] |
Zhang X, Falagas ME, Vardakas KZ , et al. Systematic review and meta-analysis of the efficacy and safety of therapy with line-zolid containing regimens in the treatment of multidrug-resis-tant and extensively drug-resistant tuberculosis. J Thorac Dis, 2015,7(4):603-615.
|
[28] |
Sun F, Ruan Q, Wang J , et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Agents Chemother, 2014,58(10):6297-6301.
doi: 10.1128/AAC.02784-14
URL
|
[29] |
Li H, Lu J, Liu J , et al. Linezolid is associated with improved early outcomes of childhood tuberculous meningitis. Pediatr Infect Dis J, 2016,35(6):607-610.
doi: 10.1097/INF.0000000000001114
URL
|
[30] |
Lee JK, Lee JY, Kim DK , et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. Lancet Infect Dis, 2019,19(1):46-55.
doi: 10.1016/S1473-3099(18)30480-8
URL
|
[31] |
Van AD, Maug AK, Salim MA , et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010,182(5):684-692.
doi: 10.1164/rccm.201001-0077OC
URL
|